Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.43 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4551268 | 0.98 | ALDH1A1 (0.56) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| Fumaric Acid SCHEMBL725726 | 0.89 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| Maleic Acid SCHEMBL725725 | 0.89 | ALDH1A1 (0.52) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL260785 | 0.88 | ALDH1A1 (0.50) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL260096 | 0.87 | ALDH1A1 (0.53) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL12179926 | 0.78 | ALDH1A1 (0.55) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL27938674 | 0.76 | ALDH1A1 (0.56) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL6259547 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| Nitric Acid SCHEMBL31591110 | 0.75 | ALDH1A1 (0.51) | ALDH1A1MAPTKMT2AKDM4EMEN1 | |
| SCHEMBL2076979 | 0.75 | ALDH1A1 (0.51) | ALDH1A1MAPTKMT2AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117224483-B | 2- (4-Methylthiazol-5-yl) ethyl nitrate brain-targeted liposome applicable to heat assisted treatment | 山东京卫制药有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-117224483-A | 2- (4-methylthiazol-5-yl) ethyl nitrate brain-targeted liposome applicable to heat assisted treatment | 山东京卫制药有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-108239040-B | Preparation method of nitric acid 2- (4-methylthiazol-5-yl) ethyl ester hydrochloride | 中国医学科学院药物研究所 | 2021-12-07 | — | — | CN | claimed |
| EP-1753734-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2007-02-21 | — | — | EP | claimed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | claimed |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | claimed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | claimed |
| CN-117224483-B | 2- (4-Methylthiazol-5-yl) ethyl nitrate brain-targeted liposome applicable to heat assisted treatment | 山东京卫制药有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117224483-B | 2- (4-Methylthiazol-5-yl) ethyl nitrate brain-targeted liposome applicable to heat assisted treatment | 山东京卫制药有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117224483-B | 2- (4-Methylthiazol-5-yl) ethyl nitrate brain-targeted liposome applicable to heat assisted treatment | 山东京卫制药有限公司 | 2024-05-10 | — | — | CN | disclosed |
| US-20240024293-A1 | NOMETHIAZOLES AS A TREATMENT FOR RETT SYNDROME | REVIVO THERAPEUTICS (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240024293-A1 | NOMETHIAZOLES AS A TREATMENT FOR RETT SYNDROME | REVIVO THERAPEUTICS (US) | 2024-01-25 | — | — | US | disclosed |
| CN-117224483-A | 2- (4-methylthiazol-5-yl) ethyl nitrate brain-targeted liposome applicable to heat assisted treatment | 山东京卫制药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | RENOPHARM LTD. (IL) | 2007-01-25 | — | — | US | disclosed |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-08-17 | — | — | US | disclosed |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | RENOPHARM LTD. (IL) | 2006-03-30 | — | — | US | disclosed |
| WO-2005105765-A1 | NITRIC OXIDE DONORS AND USES THEREOF | RENOPHARM LTD. (IL) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183912-A1 | Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof | NOS2, NOS1, NOS3 | ALDH1A1 274/4885MAPT 3098/4885KMT2A 3145/4885 |
| US-20060183718-A1 | Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof | NOS2, NOS1, NOS3 | ALDH1A1 202/4885MAPT 4152/4885KMT2A 2571/4885 |
| US-20060183913-A1 | Thiazole-based nitric oxide donors having acyl substuent(s) and uses thereof | NOS2, NOS1, SQOR | ALDH1A1 240/4885MAPT 4020/4885KMT2A 1975/4885 |
| US-20060069139-A1 | Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof | NOS2, NOS1, NOS3 | ALDH1A1 337/4885MAPT 3663/4885KMT2A 3551/4885 |
| US-20240024293-A1 | NOMETHIAZOLES AS A TREATMENT FOR RETT SYNDROME | RARS2, RET, PNMT | ALDH1A1 1473/4885MAPT 35/4885KMT2A 152/4885 |
| US-20070021382-A1 | Nitric oxide donors and uses thereof | NOS2, NOS1, NOS3 | ALDH1A1 475/4885MAPT 4219/4885KMT2A 2960/4885 |
| US-20060069138-A1 | Thiazole-based nitric oxide donors having alkyl substuent(s) and uses thereof | NOS1, NOS2, NOS3 | ALDH1A1 204/4885MAPT 4115/4885KMT2A 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.